---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-086806"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T11:18:45.841878+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Innoviva Q2 2023: GSK royalties $65.7M, XACDURO FDA approved, net income $1.3M

## Summary
- GSK royalties of $65.7M (RELVAR/BREO $54.4M, ANORO $11.3M) vs $111.7M in Q2 2022 due to TRELEGY royalty sale.
- Net product sales $15.7M (GIAPREZA $11.2M, XERAVA $4.5M); $3.0M license milestone from XACDURO FDA approval.
- Net income $1.3M ($0.02 basic EPS) vs $0.9M ($0.01) in Q2 2022; cash + receivables $254M.
- Repurchased 775,504 shares for $9.2M in Q2 2023; invested $25M in Armata (NYSE: ARMP) on July 11, 2023.
- On May 23, 2023, FDA approved XACDURO for HABP/VABP caused by Acinetobacter; launch expected H2 2023.

## SEC filing metadata
- accession: 0001104659-23-086806
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000110465923086806/0001104659-23-086806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000110465923086806/tm2322589d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-086806
- JSON: https://secwatch.observer/filing/0001104659-23-086806.json
- Plain text: https://secwatch.observer/filing/0001104659-23-086806.txt

## Key facts
- Earnings Releases
  Innoviva, Inc. reported the second quarter ended June 30, 2023 results: net income $1.3 million, or $0.02 basic per share, EPS $0.02 basic per share.
  - Period: the second quarter ended June 30, 2023
  - Net income: $1.3 million, or $0.02 basic per share
  - EPS: $0.02 basic per share
  - Result: reported results
  source text: Innoviva, Inc. (the "Company") issued a press release regarding its results of operations and financial condition for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1080014/000110465923086806/0001104659-23-086806-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.